Companies: 10,795·Total market cap: $144.5T
Roivant Sciences Ltd.

Roivant Sciences Ltd.

ROIVNASDAQHealthcare● Active
$28.49
$-0.09(-0.31%)
Market Cap$20.5B
P/E Ratio—
52W High$32.793
52W Low$10.705
Overview
Foreign Private Issuer · Files 20-F / 6-K

Roivant Sciences Ltd. (ROIV) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001635088 · ROIV · NASDAQ · as of Jun 8, 2026

Filing snapshot

911
Total Filings
4
Latest Form
2026-05-22
Most Recent
2020
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001635088 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-05-20
Fiscal Year End
May 20, 2026
Accession No.
0001635088-26-000061
Primary Document
roiv-20260331.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001635088 · Accession 0001635088-26-000061

Latest Key Filings

6-KQuarterly Report

No recent filings

8-KCurrent Report
8-K
2026-05-20Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
S-8Employee Stock Plan Registration
FORM S-8
2026-05-20
View
10-KAnnual Report
10-K
2026-05-20
View
8-KCurrent Report
8-K
2026-05-20
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-12
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-06
View
8-KCurrent Report
8-K
2026-04-02
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-27
View
8-K/ACurrent Report (Amended)
8-K/A
2026-03-23
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-06
View
8-KCurrent Report
8-K
2026-03-03
View
8-KCurrent Report
8-K
2026-03-03
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-13
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-11
View
10-QQuarterly Report
10-Q
2026-02-06
View
Showing 1–15 of 322 filingsForm 4 / 144 hidden· 911 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001635088  |  Exchange: NASDAQ · Healthcare

Roivant Sciences Ltd. (NASDAQ: ROIV) has submitted 911 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001635088, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Roivant Sciences Ltd.'s most comprehensive regulatory disclosure. The most recent Roivant Sciences Ltd. 10-K was filed on 2026-05-20 for fiscal year ending 2026. Historical ROIV 10-K annual reports are available from 2015 through 2026.

Investors researching Roivant Sciences Ltd. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
RVMD SEC Filings →RPRX SEC Filings →EXAS SEC Filings →MRNA SEC Filings →JAZZ SEC Filings →BBIO SEC Filings →ASND SEC Filings →IONS SEC Filings →
→ ROIV Financials→ ROIV Earnings→ ROIV Insider Trades

Frequently Asked Questions

ROIV SEC Filings · 8 questions

Roivant Sciences Ltd. (ROIV) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 911 filings and access original documents at no cost. Roivant Sciences Ltd.'s CIK is 0001635088.

ROIV SEC filingsRoivant Sciences Ltd. SEC documentsfind ROIV 10-K